JUMPCODE Genomics
San Diego, US · Founded 2016 · Delaware corporation · 7 employees on LinkedIn · 2 known investors
Jumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers. Its technology is used in basic research, infectious disease, oncology, and consumer genomics.
Founders & leadership
DM
David Michael SalterExecutive
MS
Mike SalterCEO/President
EC
Eugene ChenNamed on SEC filing
KB
Keith BrownNamed on SEC filing
JR
Joel RotroffNamed on SEC filing
Board
CT
JL
Joseph LeeBoard director
KM
Investors · 2
Reported raises · per SEC filings
Form D private placements$38.7M disclosed across 5 rounds · 2018–2024
▶$3.5MraisedAug 2024 · 8 investors · BiotechnologyRule 506(b)
▶$3.5MraisedAug 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David Michael SalterExecutive Officer, Director
- Court TurnerDirector
- Joseph LeeDirector
- Offering amount
- $11.5M
- Amount sold
- $3.5M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.2MraisedMay 2023 · 7 investors · BiotechnologyRule 506(b)
▶$9.2MraisedMay 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yaron HakakExecutive Officer, Director
- Frank WitneyDirector
- Court TurnerDirector
- Kirk MalloyDirector
- Dan KidleDirector
- Brandon PoeExecutive Officer
- Offering amount
- $16.1M
- Amount sold
- $9.2M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21MraisedDec 2020 · 5 investors · BiotechnologyRule 506(b)
▶$21MraisedDec 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Keith BrownExecutive Officer
- Yaron HakakExecutive Officer, Director
- Dan KidleDirector
- Kirk MalloyDirector
- Kevin LiDirector
- Frank WitneyDirector
- Michael LiangDirector
- Offering amount
- $21M
- Amount sold
- $21M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$1.5MraisedFeb 2020 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedFeb 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Keith BrownExecutive Officer, Director
- Eugene ChenDirector
- Kevin LiDirector
- Joel RotroffDirector
- Kirk MalloyDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$3.5MraisedSep 2018 · 4 investors · OtherRule 506(b)
▶$3.5MraisedSep 2018 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eugene ChenDirector
- Keith BrownExecutive Officer, Director
- Joel RotroffDirector
- Kirk MalloyDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Oup11 shared keywordsOxford University Press publishes research, educational, and reference materials, including reports on reading and children's learning, and reference resources such as its dictionary "Word of the Day." It serves readers, educators, and learners across a wide range of subjects worldwide.
IDbyDNA10 shared keywordsScalable, high throughput DNA sequencing platforms.
Transcode Therapeutics6 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
10x Genomics 1-color6 shared keywords10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.
Companies competing with JUMPCODE Genomics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does JUMPCODE Genomics do?
- Jumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers. Its technology is used in basic research, infectious disease, oncology, and consumer genomics.
- Who are JUMPCODE Genomics's investors?
- JUMPCODE Genomics's investors include Arboretum Ventures, LYZZ Capital.
- How much funding has JUMPCODE Genomics raised?
- JUMPCODE Genomics has disclosed $38.7M raised across 5 rounds.
- Where is JUMPCODE Genomics headquartered?
- JUMPCODE Genomics is headquartered in San Diego, US.